GSK Faces Scrutiny Over Misleading Omjjara Prescription Information
On April 15, 2025, the Prescription Medicines Code of Practice Authority (PMCPA) determined that GlaxoSmithKline (GSK) breached ethical and regulatory standards concerning its drug Omjjara. The PMCPA found that the prescribing information for Omjjara was misleading, particularly for women using hormonal contraceptives, by failing to adequately communicate the need for additional pregnancy prevention measures.
Omjjara is prescribed for adults with myelofibrosis, a rare bone marrow cancer, and for those suffering from moderate to severe anemia. The PMCPA’s findings highlight concerns about the accuracy of information provided to patients and healthcare professionals.
In response, a GSK spokesperson stated, “We take adherence to industry codes and regulations very seriously.” This incident adds to GSK’s history of regulatory challenges, including a $3 billion settlement in 2012 over allegations of illegal marketing practices and failure to report safety data.
You May Interested In
2026-10-04
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Is Evonik’s Massive Global Expansion of Hydroxyl-Terminated Polybutadiene (HTPB) a Technological Ambition — or a Geopolitical Gamble?
-
BASF Moves to Sell 4,400 Employee Homes—Union Fury Reveals the Survival Math of a Chemical Giant
-
The Most Striking Thing in BASF’s 2025 Results Isn’t Profit — It’s “Cutting Weight” and “Stopping the Bleeding” at the Same Time
-
BASF Battles Market Turmoil as Profits Slide
-
Beiersdorf Launches Eucerin Skincare Brand in Japan
-
From Desert Sands to Dining Tables: Arab Food & Beverage Sector Emerges as Investment Powerhouse
-
Yulong Petrochemical’s 100,000-ton MMA Project Comes Online Amid a “Deep V-Shaped Rebound” — Opportunity or Hidden Risk?
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
-
AstraZeneca’s Wainua Fails Phase III Heart Trial, Wiping Out About $27 Billion in Market Value
-
Exit! Why Did Clariant Divest Its Venezuelan Business at a “Low Price”?
Recommend Reading
-
![“A Single Tube of Adhesive—Enough to Shake the Global Chemical Chessboard?”: The Hidden Power Struggle Behind the FTC’s Block of Henkel’s Liquid Nails Deal]()
“A Single Tube of Adhesive—Enough to Shake the Global Chemical Chessboard?”: The Hidden Power Struggle Behind the FTC’s Block of Henkel’s Liquid Nails Deal
-
![BASF's Intensified Moves from May to June: Plant Closures, Divestitures, and Transformation in Sync]()
BASF's Intensified Moves from May to June: Plant Closures, Divestitures, and Transformation in Sync
-
![Can the Manufacturing Sector Withstand Dow’s April Polyethylene Price Doubling?]()
Can the Manufacturing Sector Withstand Dow’s April Polyethylene Price Doubling?
-
![Nouryon's Production Facilities in China Have Obtained Halal Certification for Personal Care Ingredients]()
Nouryon's Production Facilities in China Have Obtained Halal Certification for Personal Care Ingredients
-
![$15 Billion Invested in China: AstraZeneca Builds an “Innovation Hub” While Some Are Still Waiting for the Windfall]()
$15 Billion Invested in China: AstraZeneca Builds an “Innovation Hub” While Some Are Still Waiting for the Windfall
-
![Business Society’s Market Outlook for Epichlorohydrin on September 7, 2026: Fluctuating (Bullish) Trend]()
Business Society’s Market Outlook for Epichlorohydrin on September 7, 2026: Fluctuating (Bullish) Trend
-
![November Maleic Anhydride Prices Generally Decline in China]()
November Maleic Anhydride Prices Generally Decline in China
-
![Business Society’s Market Outlook for Phthalic Anhydride on September 7, 2026: Relatively Resilient with a Bias Toward Stability]()
Business Society’s Market Outlook for Phthalic Anhydride on September 7, 2026: Relatively Resilient with a Bias Toward Stability
-
![Business Society’s Market Outlook for Acrylic Acid on September 7, 2026: Strong Consolidation]()
Business Society’s Market Outlook for Acrylic Acid on September 7, 2026: Strong Consolidation
-
![2026 Q1 Chemical Giant Earnings: Supply Contraction, Flat Demand, Full-Scale]()
2026 Q1 Chemical Giant Earnings: Supply Contraction, Flat Demand, Full-Scale "Defense Priority"
